Bidding war breaks out for DC’s Vanda Pharmaceuticals

Just days after D.C.-based Vanda Pharmaceuticals said it had received an unsolicited buyout offer from a U.K. drug company, a suitor Vanda had previously rejected has returned with a sweetened offer.

Future Pak, a Michigan-based contract manufacturing and packaging company in the pharmaceuticals industry, has raised its offer from $8.50 to $9 a share, valuing Vanda at as much as $524 million. Vanda rejected Future Pak’s original offer last month, saying it substantially undervalued the company.

Future Pak’s offer trumps that of Cambridge, U.K.-based Cycle Pharmaceuticals, which valued Vanda at about $446 million.

Vanda said it will review Future Pak’s new offer, along with the one received from Cycle Pharmaceuticals.

Vanda has two commercialized drugs: Hetlioz, which is used to treat sleeping disorders, and Fanapt, a treatment for schizophrenia. Fanapt recently won FDA approval for use as a treatment for bipolar disorder.

Vanda is developing treatments for jet lag, sea sickness and stage fright.

Get breaking news and daily headlines delivered to your email inbox by signing up here.

© 2024 WTOP. All Rights Reserved. This website is not intended for users located within the European Economic Area.

Jeff Clabaugh

Jeff Clabaugh has spent 20 years covering the Washington region's economy and financial markets for WTOP as part of a partnership with the Washington Business Journal, and officially joined the WTOP newsroom staff in January 2016.

Federal News Network Logo
Log in to your WTOP account for notifications and alerts customized for you.

Sign up